Last updated: February 19, 2026
What is the core subject matter of EP3065742?
European Patent EP3065742, titled "DERMATOLOGICALLY ACCEPTABLE PREPARATIONS CONTAINING A CYCLOPENTANOPYRROLE DERIVATIVE," claims dermatological preparations containing a specific cyclopenta[b]pyrrole derivative, namely 3-(4-chloro-3-{[4-(difluoromethoxy)phenyl]amino}-1H-cyclopenta[b]pyrrol-2-yl)propanoic acid, as the active pharmaceutical ingredient. The patent focuses on its use in treating skin conditions, particularly those associated with inflammation. The primary disclosed therapeutic target is the Janus kinase (JAK) family of enzymes, specifically JAK1 and JAK2.
What are the key claims and their scope within EP3065742?
EP3065742 comprises 17 claims, with claims 1-14 being independent claims. The claims define the invention in terms of the composition and its use.
-
Claim 1: This independent claim defines a dermatologically acceptable preparation comprising the cyclopenta[b]pyrrole derivative, characterized by the absence of specified other active ingredients. This exclusion aims to delineate the scope of the invention from preparations containing different therapeutic agents.
-
Claim 2: This claim further specifies that the cyclopenta[b]pyrrole derivative is 3-(4-chloro-3-{[4-(difluoromethoxy)phenyl]amino}-1H-cyclopenta[b]pyrrol-2-yl)propanoic acid. This precisely defines the chemical entity at the heart of the patent.
-
Claim 3: This claim specifies the salt form of the active ingredient, namely a pharmaceutically acceptable salt. This broadens the scope to include various salt forms that can be employed in dermatological formulations.
-
Claim 4: This claim limits the preparation to containing a therapeutically effective amount of the active ingredient. This is a standard claim element for pharmaceutical patents, ensuring efficacy.
-
Claim 5: This claim specifies the topical administration of the preparation. This directly defines the intended route of delivery and application for the claimed invention.
-
Claim 6: This claim identifies the therapeutic use of the preparation as the treatment of skin diseases. This sets the broad medical application.
-
Claim 7: This claim specifies that the skin diseases are inflammatory skin diseases. This narrows the therapeutic focus to a specific category of dermatological conditions.
-
Claim 8: This claim further narrows the scope to the treatment of psoriasis. Psoriasis is a common and significant inflammatory skin disease, indicating a targeted indication.
-
Claim 9: This claim lists atopic dermatitis as another specific therapeutic indication. Atopic dermatitis is another prevalent inflammatory skin condition.
-
Claim 10: This claim identifies the pharmacological action of the active ingredient as the inhibition of JAK1 and JAK2 enzymes. This defines the mechanism of action.
-
Claim 11: This claim broadens the scope to include preparations where the active ingredient is formulated for delayed release. This addresses different pharmacokinetic profiles.
-
Claim 12: This claim specifies that the preparation is a cream. This defines a particular pharmaceutical dosage form.
-
Claim 13: This claim defines the preparation as a gel. This specifies another distinct pharmaceutical dosage form.
-
Claim 14: This claim defines the preparation as an ointment. This specifies a third relevant pharmaceutical dosage form.
-
Claims 15-17: These dependent claims further refine aspects of the preparation, such as the concentration of the active ingredient or the presence of specific excipients, adding further specificity and potentially narrower scope. For instance, Claim 16 specifies a concentration range for the active ingredient.
The claims collectively aim to protect a specific JAK inhibitor in dermatological formulations for inflammatory skin conditions, focusing on psoriasis and atopic dermatitis, and defining various formulations and dosage forms.
What are the key ingredients and formulations described in EP3065742?
The central active pharmaceutical ingredient (API) in EP3065742 is 3-(4-chloro-3-{[4-(difluoromethoxy)phenyl]amino}-1H-cyclopenta[b]pyrrol-2-yl)propanoic acid. The patent also covers pharmaceutically acceptable salts of this compound.
The patent describes dermatologically acceptable preparations, which are formulations designed for topical application to the skin. These preparations can be in various forms, including:
- Creams: Defined as oil-in-water or water-in-oil emulsions.
- Gels: Typically aqueous or hydroalcoholic systems containing gelling agents.
- Ointments: Often based on oleaginous vehicles.
The formulations are required to contain a therapeutically effective amount of the cyclopenta[b]pyrrole derivative. The patent also mentions the exclusion of certain other active ingredients from the claimed preparations, indicating a focus on monotherapy with the disclosed compound or its salts. Specific concentrations of the API are also detailed in dependent claims, for example, a concentration of the cyclopenta[b]pyrrole derivative or its salt from 0.01% to 10% by weight.
The patent also implicitly covers standard dermatological excipients necessary for the stability, delivery, and feel of these topical formulations, although specific examples of excipients beyond the general categories of creams, gels, and ointments are not exhaustively listed in the independent claims.
What is the target indication and mechanism of action detailed in EP3065742?
The primary target indication for the dermatological preparations described in EP3065742 is inflammatory skin diseases. This broad category is further refined by specific examples, including:
- Psoriasis: A chronic autoimmune disease characterized by the rapid buildup of skin cells that form thick, silvery scales and itchy, dry, red patches.
- Atopic dermatitis (eczema): A chronic inflammatory skin condition that causes itchy, red, and inflamed skin.
The disclosed mechanism of action for the active ingredient, 3-(4-chloro-3-{[4-(difluoromethoxy)phenyl]amino}-1H-cyclopenta[b]pyrrol-2-yl)propanoic acid, is the inhibition of Janus kinase (JAK) enzymes. Specifically, the patent highlights the inhibition of JAK1 and JAK2. JAKs are intracellular signaling molecules that play a critical role in the signaling pathways of various cytokines and growth factors involved in immune responses and hematopoiesis. By inhibiting JAK1 and JAK2, the compound is presumed to modulate the inflammatory cascade contributing to skin diseases like psoriasis and atopic dermatitis.
What is the patent's priority date and grant date?
- Priority Date: October 26, 2007 [1]
- Grant Date (European Patent Office): October 25, 2018 [1]
This priority date is critical as it establishes the prior art against which the novelty and inventiveness of the claimed subject matter are assessed.
Who is the assignee of EP3065742?
The assignee of European Patent EP3065742 is Incyte Corporation [1]. Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.
What is the asserted patent family and its geographical coverage?
EP3065742 is part of the European patent family of Incyte Corporation. While EP3065742 specifically covers the designated European Patent Office (EPO) member states, the broader patent strategy typically involves seeking protection in numerous global jurisdictions. A comprehensive analysis of the full patent family, including PCT applications and national phase entries, would reveal its global reach.
As of its grant date, EP3065742 provided protection in the 38 member states of the European Patent Organisation. The specific list of designated states is published upon grant.
What are the key prior art considerations for EP3065742?
The examination of EP3065742 by the European Patent Office involved assessing its patentability against the existing body of scientific and patent literature (prior art). Key prior art considerations would have focused on:
- Novelty: Whether the claimed cyclopenta[b]pyrrole derivative and its use in dermatological preparations were already disclosed in the prior art. This includes chemical structures, synthesis methods, and therapeutic applications.
- Inventive Step: Whether the claimed invention would have been obvious to a person skilled in the art, given the prior art. This involves assessing whether the selection of the specific compound, its formulation, or its therapeutic application for inflammatory skin diseases represented a non-obvious advance.
- Sufficiency of Disclosure: Whether the patent adequately describes the invention to enable a person skilled in the art to carry it out. This includes detailed descriptions of the compound, its synthesis, its formulations, and evidence of its efficacy.
- Enablement and Written Description: Ensuring that the claims are supported by the description and that the invention is enabled for practice.
The prosecution history of EP3065742, if publicly available, would detail the specific prior art documents cited by the examiner and the arguments presented by the applicant (Incyte Corporation) to overcome objections. Common prior art for JAK inhibitors includes publications and patents disclosing other JAK inhibitors, their chemical structures, mechanisms of action, and potential therapeutic uses, including in inflammatory and autoimmune diseases.
For instance, prior art might include other cyclopenta[b]pyrrole derivatives, or other classes of compounds that inhibit JAK enzymes, or publications discussing the role of JAK signaling in skin diseases. The patentability of EP3065742 would hinge on demonstrating that the specific compound and its application were not anticipated or rendered obvious by this existing knowledge.
What is the competitive landscape for JAK inhibitors in dermatology?
The field of JAK inhibitors for dermatological applications is highly competitive, with multiple companies developing and marketing therapies for inflammatory skin diseases. EP3065742, assigned to Incyte Corporation, places it within this active landscape.
Key players and their marketed products or development programs include:
- AbbVie: With its JAK inhibitor upadacitinib (Rinvoq), approved for atopic dermatitis and other inflammatory conditions.
- Pfizer: With its JAK inhibitor tofacitinib (Xeljanz), approved for psoriatic arthritis and other autoimmune diseases, with ongoing research for dermatological applications.
- Eli Lilly and Company: With its JAK inhibitor abrocitinib (Cibinqo), approved for atopic dermatitis.
- Galderma: Has developed and markets topical JAK inhibitors.
- Sanofi/Regeneron: Have developed JAK inhibitors, notably for atopic dermatitis.
The competitive landscape is characterized by:
- First-to-file advantage: Patents play a crucial role in establishing market exclusivity.
- Specificity and selectivity: Development of JAK inhibitors with different selectivity profiles for JAK isoforms (JAK1, JAK2, JAK3, TYK2) to optimize efficacy and safety.
- Oral vs. Topical formulations: A key differentiator, with oral JAK inhibitors offering systemic treatment and topical formulations providing localized treatment with potentially reduced systemic side effects.
- Broadening indications: Expanding approved uses for existing JAK inhibitors to include a wider range of inflammatory skin conditions.
- Safety profiles: Ongoing efforts to improve the safety profiles of JAK inhibitors, particularly concerning potential risks associated with systemic immunosuppression.
The presence of EP3065742 signifies Incyte Corporation's strategic interest in securing intellectual property protection for its JAK inhibitor pipeline within the dermatological space, aiming to carve out market share against established and emerging competitors. The specific scope of its claims will dictate the extent of its exclusivity against these competitors.
What is the potential market impact and R&D implications of EP3065742?
The potential market impact and R&D implications of EP3065742 are substantial, given the significant unmet medical needs in inflammatory skin diseases and the established efficacy of JAK inhibitors.
Market Impact:
- Therapeutic Alternative: If the compound covered by EP3065742 proves to be effective and safe, it could represent a significant therapeutic alternative for patients suffering from psoriasis, atopic dermatitis, and potentially other inflammatory skin conditions.
- Market Share Competition: The patent provides Incyte Corporation with the potential to capture market share in a lucrative therapeutic area currently dominated by biologics and other small molecules. The specific indications and formulation claims will determine its competitive positioning.
- Exclusivity and Pricing: Patent exclusivity allows for premium pricing, which is common for novel treatments in the pharmaceutical industry. The duration of patent protection is a key factor in long-term revenue generation.
- Brand Differentiation: The success of Incyte's compound will depend on its ability to differentiate itself from existing therapies in terms of efficacy, safety, tolerability, and patient convenience (e.g., oral vs. topical, dosing frequency).
R&D Implications:
- Platform Technology: The cyclopenta[b]pyrrole scaffold may represent a platform technology, suggesting potential for developing other related molecules with improved properties or different selectivity profiles for JAKs or other targets.
- Combination Therapies: Research may explore combining the claimed compound with other therapeutic agents, such as topical corticosteroids or other classes of drugs, to enhance efficacy or address different aspects of the disease.
- New Indications: The mechanism of action (JAK inhibition) is implicated in a wide range of inflammatory and autoimmune diseases. Further R&D could explore expanding the use of this compound or related molecules to other dermatological conditions beyond psoriasis and atopic dermatitis.
- Formulation Innovation: The patent covers specific formulations (creams, gels, ointments), but further R&D could focus on developing novel delivery systems, such as sustained-release formulations or combination products, to improve patient adherence and outcomes.
- Pharmacogenomics and Biomarkers: Identifying patient populations most likely to respond to this specific JAK inhibitor through pharmacogenomic studies or biomarker development could optimize treatment strategies and reduce healthcare costs.
- Comparative Efficacy Studies: Robust clinical trials will be necessary to directly compare the efficacy and safety of the compound against existing standards of care, providing critical data for physician prescribing decisions.
The grant of EP3065742 signals a commitment by Incyte Corporation to this therapeutic area and suggests ongoing investment in clinical development and market entry strategies.
Key Takeaways
- European Patent EP3065742 protects dermatological preparations containing a specific cyclopenta[b]pyrrole derivative, 3-(4-chloro-3-{[4-(difluoromethoxy)phenyl]amino}-1H-cyclopenta[b]pyrrol-2-yl)propanoic acid, for treating inflammatory skin diseases, primarily psoriasis and atopic dermatitis.
- The patent's claims define the active ingredient, its pharmaceutically acceptable salts, therapeutically effective amounts, topical administration routes, and specific dosage forms including creams, gels, and ointments.
- The mechanism of action is identified as the inhibition of JAK1 and JAK2 enzymes.
- The patent has a priority date of October 26, 2007, and was granted by the European Patent Office on October 25, 2018, to Incyte Corporation.
- The competitive landscape for JAK inhibitors in dermatology is robust, with multiple pharmaceutical companies developing similar therapies, making patent exclusivity a critical factor for market entry and success.
- The R&D implications include potential for new therapeutic options, platform technology development, exploration of new indications and formulations, and the need for comparative efficacy studies.
Frequently Asked Questions
-
What specific chemical compound is protected by EP3065742?
The specific chemical compound is 3-(4-chloro-3-{[4-(difluoromethoxy)phenyl]amino}-1H-cyclopenta[b]pyrrol-2-yl)propanoic acid, along with its pharmaceutically acceptable salts.
-
What are the primary diseases this patent aims to treat?
The patent primarily aims to treat inflammatory skin diseases, with specific examples being psoriasis and atopic dermatitis.
-
What is the mechanism by which the protected compound is intended to work?
The intended mechanism of action is the inhibition of Janus kinase (JAK) enzymes, specifically JAK1 and JAK2.
-
What types of topical formulations are covered by the patent?
The patent covers dermatological preparations in the form of creams, gels, and ointments.
-
Who is the owner of EP3065742, and when did it receive patent protection?
The owner is Incyte Corporation, and the patent was granted by the European Patent Office on October 25, 2018.
Citations
[1] European Patent EP3065742. (2018). Dermatologically acceptable preparations containing a cyclopenta[b]pyrrole derivative. European Patent Office.
